MEDIPOST has revealed that their Alzheimer’s dementia treatment ‘NEUROSTEM-AD’, which uses stem cells have obtained the 1. 2a clinical trial approval from the Food and Drug Administration.

This clinical trial had challenged the conquering dementia using stem cells for the first time in the world, which is gaining the interest of the large pharmaceutical companies in America and Europe, as well as the entire world’s medical world and academic world.

Following the Food and Drug Administration’s approval, MEDIPOST will continue with the joint examination of the effectiveness of this treatment together with Samsung Seoul Hospital for the next two years, following the previous clinical trial that has observed the safety of ‘NEUROSTEM-AD’.

‘NEUROSTEM-AD’ contains stem cells extracted from cord blood as the main composition, and suppresses the extinction of brain nerve cells and decreases amyloid beta protein, which causes toxins in neurons.

Dementia can also fundamentally be treatment through the regeneration of nerves and the decrease of substances that cause dementia.

MEDIPOST successfully completed the first clinical trial of ‘NEUROSTEM-AD’ on December 2011 to evaluate its safety, and has also verified the effectiveness of treatment in the previous clinical trial conducted on animals.

Unlike the single administration within the brain through surgical procedures in the previous clinical trial, MEDIPOST plans to increase convenience and effectiveness with the method of non-surgically administrating the medicine three times in the cerebrospinal fluid by changing the method of administering the medicine.